{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:05:01Z","timestamp":1788930301502,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tafamidis is the only disease-modifying therapy approved to treat patients in the United States with transthyretin amyloid cardiomyopathy (ATTR-CM), which most commonly affects patients aged\u2009\u2265\u200965\u00a0years. The manufacturer operates a patient assistance program (PAP) to support access to tafamidis. This study conducted Privacy Preserving Record Linking (PPRL) using Datavant tokens to match patients across Medicare prescription drug plan (PDP) and PAP databases to evaluate the impact of PAPs on treatment exposure classification, adherence, and persistence determined using Medicare PDP data alone. We found 35% of Medicare PDP patients received tafamidis through the PAP only; 14% through both Medicare PDP and the PAP, and 51% through Medicare PDP only. Adherence and persistence were comparable between these cohorts but underestimated among patients who received\u2009\u2265\u20092 prescriptions through Medicare PDP and\u2009\u2265\u20091 through the PAP when solely using Medicare data versus pooled Medicare and PAP data (modified Medication Possession Ratio: 84% [69%\u2009\u2265\u200980% adherent] vs. 96% [93%]; Proportion of Days Covered: 77% [66%\u2009\u2265\u200980% adherent] vs. 88% [88%]; mean days to discontinuation: 186 vs. 252; total discontinuation: 13% vs. 11%). Cross-database PPRL is a valuable method to build more complete treatment journeys and reduce the risk of exposure misclassification in real-world analyses.<\/jats:p>","DOI":"10.1038\/s41598-024-62660-5","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T12:01:58Z","timestamp":1721044918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adherence and persistence to tafamidis treatment among Medicare beneficiaries in the presence of a patient assistance program"],"prefix":"10.1038","volume":"14","author":[{"given":"Haechung","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cera","family":"Cantu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindi","family":"Pankratova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kemner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Alvir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"62660_CR1","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1097\/MLR.0b013e31805371bf","volume":"45","author":"S Crystal","year":"2007","unstructured":"Crystal, S., Akincigil, A., Bilder, S. & Walkup, J. T. Studying prescription drug use and outcomes with Medicaid claims data: strengths, limitations, and strategies. Med. Care 45, S58\u2013S65 (2007).","journal-title":"Med. Care"},{"key":"62660_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/cpt.359","volume":"100","author":"KJ Lin","year":"2016","unstructured":"Lin, K. J. & Schneeweiss, S. Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs. Clin. Pharmacol. Ther. 100, 147\u2013159 (2016).","journal-title":"Clin. Pharmacol. Ther."},{"key":"62660_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1055\/a-1910-4154","volume":"13","author":"EV Bernstam","year":"2022","unstructured":"Bernstam, E. V. et al. Real-world matching performance of deidentified record-linking tokens. Appl. Clin. Inform. 13, 865\u2013873 (2022).","journal-title":"Appl. Clin. Inform."},{"key":"62660_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/amiajnl-2013-001744","volume":"21","author":"E Joffe","year":"2014","unstructured":"Joffe, E. et al. A benchmark comparison of deterministic and probabilistic methods for defining manual review datasets in duplicate records reconciliation. J. Am. Med. Inf. Assoc. 21, 97\u2013104 (2014).","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"62660_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cpt.2480","volume":"111","author":"S Dagenais","year":"2022","unstructured":"Dagenais, S., Russo, L., Madsen, A., Webster, J. & Becnel, L. Use of real-world evidence to drive drug development strategy and inform clinical trial design. Clin. Pharmacol. Ther. 111, 77\u201389 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"62660_CR6","unstructured":"Datavant. Overview of Datavant\u2019s de-identifying and linking technology for structured data. https:\/\/datavant.com\/wp-content\/uploads\/dlm_uploads\/2018\/09\/WhitePaper_-De-Identifying-and-Linking-Structured-Data.pdf."},{"key":"62660_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s13104-022-06243-5","volume":"15","author":"D Kiernan","year":"2022","unstructured":"Kiernan, D. et al. Establishing a framework for privacy-preserving record linkage among electronic health record and administrative claims databases within PCORnet\u00ae, the National Patient-Centered Clinical Research Network. BMC Res Notes 15, 337 (2022).","journal-title":"BMC Res Notes"},{"key":"62660_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fpubh.2017.00034","volume":"5","author":"AP Brown","year":"2017","unstructured":"Brown, A. P., Ferrante, A. M., Randall, S. M., Boyd, J. H. & Semmens, J. B. Ensuring privacy when integrating patient-based datasets: New methods and developments in record linkage. Front. Public Health. 5, 34 (2017).","journal-title":"Front. Public Health."},{"key":"62660_CR9","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W. & Maurer, M. S. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 2872\u20132891 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"62660_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles, R. M. et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 7, 709\u2013716 (2019).","journal-title":"JACC Heart Fail."},{"key":"62660_CR11","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/DDDT.S289772","volume":"15","author":"A Burton","year":"2021","unstructured":"Burton, A. et al. Drug discovery and development in rare diseases: Taking a closer look at the tafamidis story. Drug Des. Dev. Ther. 15, 1225\u20131243 (2021).","journal-title":"Drug Des. Dev. Ther."},{"key":"62660_CR12","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer, M. S. et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ. Heart Fail. 12, e006075 (2019).","journal-title":"Circ. Heart Fail."},{"key":"62660_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1353\/hpu.2011.0003","volume":"22","author":"TM Felder","year":"2011","unstructured":"Felder, T. M., Palmer, N. R., Lal, L. S. & Mullen, P. D. What is the evidence for pharmaceutical patient assistance programs? A systematic review. J. Health Care Poor Underserved. 22, 24\u201349 (2011).","journal-title":"J. Health Care Poor Underserved."},{"key":"62660_CR14","unstructured":"Pfizer Laboratories Division & Pfizer Inc. VYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis) prescribing information. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11685. (2020)."},{"key":"62660_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1001\/jamainternmed.2013.2509","volume":"173","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y., Wu, S.-H., Fendrick, A. M. & Baicker, K. Variation in medication adherence in heart failure. JAMA Int. Med. 173, 468\u2013470 (2013).","journal-title":"JAMA Int. Med."},{"key":"62660_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40545-023-00582-9","volume":"16","author":"C Cheng","year":"2023","unstructured":"Cheng, C., Donovan, G., Al-Jawad, N. & Jalal, Z. The use of technology to improve medication adherence in heart failure patients: A systematic review of randomised controlled trials. J. Pharm. Policy Pract. 16, 81 (2023).","journal-title":"J. Pharm. Policy Pract."},{"key":"62660_CR17","unstructured":"KFF. Total number of Medicare beneficiaries by type of coverage. https:\/\/www.kff.org\/medicare\/state-indicator\/total-medicare-beneficiaries\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. (2021)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62660-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62660-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62660-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T12:12:12Z","timestamp":1721045532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62660-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["62660"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-62660-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"12 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by Pfizer. HC, CP, JK, JA, and YC are employees and hold stock\/stock options in Pfizer. CC and SP are employees of Clarify Health, which was contracted and paid by Pfizer for participation in this study. Medical writing support was provided by Jennifer Bodkin of Engage Scientific Solutions and was funded by Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16261"}}